Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

NY-ESO-1 TCR

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Gilead, National Cancer Institute

Drug class:

TCR modulator, NY ESO 1 inhibitor

Related drugs:

‹

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

GSK2241658A (0)

MultiTAA T cell therapy (0)

TCRT-ESO-A2 (0)

FH-TCR-Tᴍsʟɴ (0)

HA-1 T TCR T Cell Immunotherapy (0)

MAGE A3 TCR (0)

NY-ESO-1 TCR-T cell therapy (0)

T-Plex-200-A0201/204-A0201 (0)

T-cell receptor therapy (0)

TSC-200-A0201 (0)

TSC-204-A0201 (0)

TSC-204-C0702 (0)

mono TRuC-T CD70 cell therapy (0)

multiplexed MAGEA1/PRAME TCR-T cell therapy (0)

GSK2241658A (0)

MultiTAA T cell therapy (0)

TCRT-ESO-A2 (0)

›